ASX:IPD

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

AU$143.4m

Last Updated

2021/08/02 15:43 UTC

Data Sources

Company Financials +

Executive Summary

ImpediMed Limited, a medical software technology company, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. More Details


Snowflake Analysis

Flawless balance sheet with limited growth.

Share Price & News

How has ImpediMed's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IPD is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: IPD's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

0%

IPD

-1.5%

AU Medical Equipment

-0.1%

AU Market


1 Year Return

28.0%

IPD

17.1%

AU Medical Equipment

27.3%

AU Market

Return vs Industry: IPD exceeded the Australian Medical Equipment industry which returned 17.1% over the past year.

Return vs Market: IPD matched the Australian Market which returned 27.3% over the past year.


Shareholder returns

IPDIndustryMarket
7 Day0%-1.5%-0.1%
30 Day-12.7%-3.0%0.9%
90 Day-20.0%0.04%4.5%
1 Year28.0%28.0%18.0%17.1%31.9%27.3%
3 Year-72.3%-72.6%30.0%24.3%32.7%16.8%
5 Year-93.3%-93.4%65.7%54.9%62.5%31.0%

Long-Term Price Volatility Vs. Market

How volatile is ImpediMed's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is ImpediMed undervalued compared to its fair value and its price relative to the market?

4.11x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate IPD's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate IPD's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: IPD is unprofitable, so we can't compare its PE Ratio to the Australian Medical Equipment industry average.

PE vs Market: IPD is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IPD's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IPD is good value based on its PB Ratio (4.1x) compared to the AU Medical Equipment industry average (5.1x).


Future Growth

How is ImpediMed forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

47.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IPD is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IPD is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IPD is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IPD's revenue (53.4% per year) is forecast to grow faster than the Australian market (5.3% per year).

High Growth Revenue: IPD's revenue (53.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IPD is forecast to be unprofitable in 3 years.


Past Performance

How has ImpediMed performed over the past 5 years?

3.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IPD is currently unprofitable.

Growing Profit Margin: IPD is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IPD is unprofitable, but has reduced losses over the past 5 years at a rate of 3.6% per year.

Accelerating Growth: Unable to compare IPD's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IPD is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (31.7%).


Return on Equity

High ROE: IPD has a negative Return on Equity (-75.02%), as it is currently unprofitable.


Financial Health

How is ImpediMed's financial position?


Financial Position Analysis

Short Term Liabilities: IPD's short term assets (A$24.0M) exceed its short term liabilities (A$5.8M).

Long Term Liabilities: IPD's short term assets (A$24.0M) exceed its long term liabilities (A$420.0K).


Debt to Equity History and Analysis

Debt Level: IPD is debt free.

Reducing Debt: IPD has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IPD has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: IPD has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 7.1% each year.


Dividend

What is ImpediMed current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IPD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate IPD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IPD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IPD's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IPD's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.8yrs

Average management tenure


CEO

Rick Carreon

9.08yrs

Tenure

AU$1,142,148

Compensation

Mr. Richard Carreon, also known as Rick, has been the Managing Director of ImpediMed Limited since May 9, 2015 and joined as its Chief Executive Officer and President since July 10, 2012. Mr. Carreon has e...


CEO Compensation Analysis

Compensation vs Market: Rick's total compensation ($USD839.07K) is above average for companies of similar size in the Australian market ($USD270.84K).

Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: IPD's management team is considered experienced (4.8 years average tenure).


Board Members

Experienced Board: IPD's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 44.4%.


Top Shareholders

Company Information

ImpediMed Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ImpediMed Limited
  • Ticker: IPD
  • Exchange: ASX
  • Founded: 1999
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$143.424m
  • Shares outstanding: 1.49b
  • Website: https://www.impedimed.com

Number of Employees


Location

  • ImpediMed Limited
  • 50 Parker Court
  • Unit 1
  • Pinkenba
  • Queensland
  • 4008
  • Australia

Listings


Biography

ImpediMed Limited, a medical software technology company, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/08/02 15:43
End of Day Share Price2021/08/02 00:00
Earnings2020/12/31
Annual Earnings2020/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.